Grafa News and Videos — Page 170

Biohaven (NYSE:BHVN) entered an exclusive regional licensing agreement with Ono Pharmaceutical covering its IgG degrader portfolio, with near-term payments of up to $100 million.

XPENG (NYSE:XPEV) completed the first production trial of its G9L SUV at Magna’s Graz, Austria facility, making it the fourth XPENG model to undergo production there.

LEIFRAS (NASDAQ:LFS) reported unaudited first-half fiscal 2026 revenue of JPY5,978.8 million for the six months ended June 30, up 8.9% from a year earlier.

argenx (NASDAQ:ARGX) said its Phase 2 study of FB102 in adults with celiac disease met its primary endpoint, showing a statistically significant improvement versus placebo at day 78 with a p-value of 0.0176.

argenx (NASDAQ:ARGX) will discontinue its Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren's disease after an interim analysis found the trial could not meet its primary endpoint.

CME Group (NASDAQ:CME) reported international average daily volume of 9 million contracts in the third quarter of 2026, up 22% from a year earlier.

OzCar has entered voluntary administration after secured creditors appointed administrators to assess the company's financial options.

High-Tech Metals (ASX:HTM) announced plans to change its corporate name to Beyond Discovery to reflect its strategic pivot towards gold exploration.

Zinc of Ireland (ASX:ZMI) secured firm commitments from institutional and sophisticated investors to raise $3.2 million through a share placement.

Hyperfine (NASDAQ:HYPR) expects preliminary unaudited third-quarter 2026 revenue of approximately $6 million, representing 53% sequential growth from the second quarter.